Anti-inflammatory effect, plasma effective components and therapeutic targets of Huanglian Jiedu Decoction on ulcerative colitis mice.
10.19540/j.cnki.cjcmm.20200618.201
- Author:
Xiao-Juan CUI
1
;
Zhuo LU
1
;
Si-Meng XIAO
1
;
Xue-Wan FANG
1
;
Yi-Lei WEN
2
;
Wan-Na XIONG
3
;
Kai YU
4
;
Jian-Qin LIANG
1
Author Information
1. Guangxi University of Chinese Medicine Nanning 530200, China.
2. the First Affiliated Hospital of Guangxi University of Chinese Medicine Nanning 530023, China.
3. Guangxi Medical College Nanning 530023, China.
4. Guangxi University Nanning 530004, China.
- Publication Type:Journal Article
- Keywords:
Huanglian Jiedu Decoction;
berberine;
limonin;
molecular docking;
network pharmacology;
palmatine;
plasma effective components;
ulcerative colitis
- MeSH:
Animals;
Anti-Inflammatory Agents/therapeutic use*;
Colitis, Ulcerative/drug therapy*;
Colon;
Dextran Sulfate/therapeutic use*;
Drugs, Chinese Herbal;
Mice;
Molecular Docking Simulation;
Plasma
- From:
China Journal of Chinese Materia Medica
2021;46(1):206-213
- CountryChina
- Language:Chinese
-
Abstract:
This paper was to investigate the effect of Huanglian Jiedu Decoction(HLJD) on ulcerative colitis(UC) in mice, and determine the effective components in plasma, and virtually screen its therapeutic target, and predict its mechanism. Sixty Balb/c mice were randomly divided into blank group, model group, mesalazine treatment group(0.3 g·kg~(-1)), and HLJD treatment groups(24.66, 12.33, 6.17 g·kg~(-1)). Excepted for the blank group, all the mice in HLJD and mesalazine treatment groups were gavage administration. All mice freely drank 2.5% DSS solution for seven days to induce UC. The disease activity index(DAI) was detected each day. At the end of the experiment, HE staining was used to observe the pathological changes in colon. The content of IL-1β, IL-6 and TNF-α in colon were determined by ELISA. The effective components in plasma were determined by UPLC-Q-TOF-MS. The reverse docking in PharmMapper was used to screen the component targets. The disease targets of UC were collected by searching TTD, OMIM and GeneCards databases. The intersection of the component targets and disease targets was selected as the therapeutic targets. Then the therapeutic targets were imported into the STRING for GO and KEGG enrichment analysis. Discovery Studio was used to simulate the docking between the components and the targets. RESULTS:: showed that the DAI in the model group increased significantly(P<0.05), and the number of inflammatory cells and infiltration degree increased significantly compared with the blank group. The DAI in HLJD treatment group was significantly reduced(P<0.05), and the number and infiltration degree of inflammatory cells were reduced compared with the model group. The ELISA results showed that the levels of IL-1β, IL-6 and TNF-α were increased significantly in the model group(P<0.01) compared with the blank group, and significantly down regulated in the HLJD treatment group(P<0.05) compared with the model group. After UPLC-Q-TOF-MS analyse, ten components were identified. The network pharmacology analysis showed that the action targets were significantly enriched in 129 of biological processes, such as response to organic substance, chemical and oxygen-containing compound, etc., as well as 16 of signal pathways, such as IL-17, TNF and hepatitis B signal pathways, were enriched too. The results of molecular docking showed that limonin, palmatine and berberine could bind to CASP3 and MMP9 by hydrogen bond. In conclusion, HLJD could alleviate the colonic mucosal inflammatory infiltration and mucosal damage in UC mice. The mechanism may be related to the anti-inflammatory effect on UC mice by reducing the levels of IL-1β, IL-6 and TNF-α in colon through limonin, palmatine and berberine regulating IL-17 signal pathway and TNF signal pathway via CASP3 and MMP9 meditated.
